This page is the catalog-level comparison, not a treatment page. It compares how the two compounds differ in receptor design, which live formats exist on this site, how much handling burden each route adds, and where the current AED-per-mg floor sits inside the UAE catalog.
Retatrutide wins on format range in this catalog, while tirzepatide is the cleaner dual-agonist vial route. The table below keeps that distinction visible instead of collapsing everything into a single “best compound” claim.
| Category | Retatrutide | Tirzepatide |
|---|---|---|
| Mechanism | Triple agonist GLP-1, GIP, and glucagon receptor activity. | Dual agonist GLP-1 and GIP receptor activity. |
| Live formats on this site | Four routes 30mg pen, 20mg pen, 40mg vial, and 10mg vial. | One route 10mg lyophilised research vial. |
| Documentation route | Best public proof on flagship pen Remedium 30mg carries published Janoshik batch RETP002; other retatrutide formats vary between public proof and pending/public-documentation status by page. | Cold-chain and sourcing route The current tirzepatide page emphasizes handling and supply-chain framing while batch-specific public COA is still pending. |
| Reconstitution burden | Optional Pens avoid reconstitution; vials require bacteriostatic water and a separate handling protocol. | Required The current tirzepatide route is vial-only and requires bacteriostatic water. |
| Current lowest AED per mg | AED 25/mg Lowest published ladder is the ProPeptide 40mg vial at AED 1,000 on the 5-pack tier. | AED 25/mg Lowest published ladder is the ProPeptide 10mg tirzepatide vial at AED 250 on the 5-pack tier. |
| Dispatch frame | Dubai-led cold-chain dispatch Same-day Dubai and next-day UAE when order cutoffs are met. | Dubai-led cold-chain dispatch Same-day Dubai and next-day UAE when order cutoffs are met. |
Once the compound choice is clear, the next question is format. Retatrutide currently has both pen and vial routes in the catalog, while tirzepatide is the leaner vial-only route.
300 clicks at 0.1mg per click, no reconstitution, and the strongest public batch-proof route currently on the site.
Open 30mg pen →Smaller sealed-device route for researchers who still want click-based handling rather than a vial workflow.
Open 20mg pen →Lower AED-per-mg ladder and custom reconstitution flexibility, with public COA status still pending on the current product page.
Open 40mg vial →The current dual-agonist route in this catalog: one vial format, cold-chain framing, and a lower-friction side-by-side benchmark against retatrutide.
Open tirzepatide →That is not how this page frames the decision. Retatrutide offers a triple-agonist mechanism and broader format range in this catalog, while tirzepatide offers a dual-agonist reference route with a simpler vial-only lineup. The useful question is whether you are comparing mechanisms, handling burden, or documentation status.
On the current live price ladders, the ProPeptide Retatrutide 40mg vial and ProPeptide Tirzepatide 10mg vial both reach AED 25 per mg at their lowest published multi-pack tier.
The Remedium 30mg pen and ProPeptide 20mg pen are the no-reconstitution routes currently in the catalog. The retatrutide vials and the tirzepatide vial both require bacteriostatic water and a separate handling protocol.
Use the COA library plus the product pages. The strongest public batch-proof route remains the Remedium 30mg pen, while other routes can sit in “pending” or handling-first states depending on the current page copy.